Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease

Zaiatz-Bittencourt, Vanessa; Jones, F. G.; Doherty, Glen; Ryan, Elizabeth J.

doi:10.1093/ibd/izab024

Cited by 18 publications

(3 citation statements)

References 98 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the peripheral blood of IBD patients and in vivo animal models, there is usually an increase in Th17 cells and a decrease in Treg cells [ 314 ]. Recent studies have shown that the immunometabolic processes in IBD mainly involve T cells, monocytes, macrophages, dendritic cells, and natural killer cells [ 315 ]. Immune cells produce inflammatory cytokines, which play an important role in regulating the inflammatory response process.…”

Section: Major Pathways Of Action Of Nps In the Treatment Of Ibdmentioning

confidence: 99%

Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments

2023

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic, non-specific inflammatory disease of the intestine that can be classified as ulcerative colitis (UC) and Crohn’s disease (CD). Currently, the incidence of IBD is still increasing in developing countries. However, current treatments for IBD have limitations and do not fully meet the needs of patients. There is a growing demand for new, safe, and highly effective alternative drugs for IBD patients. Natural products (NPs) are used in drug development and disease treatment because of their broad biological activity, low toxicity, and low side effects. Numerous studies have shown that some NPs have strong therapeutic effects on IBD. In this paper, we first reviewed the pathogenesis of IBD as well as current therapeutic approaches and drugs. Further, we summarized the therapeutic effects of 170 different sources of NPs on IBD and generalized their modes of action and therapeutic effects. Finally, we analyzed the potential mechanisms of NPs for the treatment of IBD. The aim of our review is to provide a systematic and credible summary, thus supporting the research on NPs for the treatment of IBD and providing a theoretical basis for the development and application of NPs in drugs and functional foods.

show abstract

Section: Major Pathways Of Action Of Nps In the Treatment Of Ibdmentioning

confidence: 99%

Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments

2023

View full text Add to dashboard Cite

show abstract

“…[ [66][67][68] miR-1-3p MiR-1-3p is downregulated in HCC cell lines. PLOS ONE [93]. ZNF354C play a vital role in the dissociation of the complex from CHD1L and BCL9 promoters to abolish the transcription inhibition, suggesting its potential target for diagnosis and treatment of HCC [60].…”

Section: Tp53mentioning

confidence: 99%

Immune–related biomarkers shared by inflammatory bowel disease and liver cancer

et al. 2022

View full text Add to dashboard Cite

It has been indicated that there is an association between inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC). However, the molecular mechanism underlying the risk of developing HCC among patients with IBD is not well understood. The current study aimed to identify shared genes and potential pathways and regulators between IBD and HCC using a system biology approach. By performing the different gene expression analyses, we identified 871 common differentially expressed genes (DEGs) between IBD and HCC. Of these, 112 genes overlapped with immune genes were subjected to subsequent bioinformatics analyses. The results revealed four hub genes (CXCL2, MMP9, SPP1 and SRC) and several other key regulators including six transcription factors (FOXC1, FOXL1, GATA2, YY1, ZNF354C and TP53) and five microRNAs (miR-124-3p, miR-34a-5p, miR-1-3p, miR-7-5p and miR-99b-5p) for these disease networks. Protein-drug interaction analysis discovered the interaction of the hub genes with 46 SRC-related and 11 MMP9- related drugs that may have a therapeutic effect on IBD and HCC. In conclusion, this study sheds light on the potential connecting mechanisms of HCC and IBD.

show abstract

“…Inflammasomes are multiprotein complexes that have a direct role in the inflammatory process by causing caspase-1, interleukin 1 (IL-1), and interleukin I8 (IL-8) to become overactive [ 143 , 144 , 145 , 146 ]. Inflammasome development is aided by five pattern recognition receptor (PRR) candidates.…”

Section: Mtor In Inflammatory Bowel Diseasesmentioning

confidence: 99%

mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer

Afzal

Altamimi

Mubeen

et al. 2022

IJMS

View full text Add to dashboard Cite

The mammalian target of rapamycin (mTOR) is the major controller of a number of important cellular activities, including protein synthesis, cell expansion, multiplication, autophagy, lysosomal function, and cellular metabolism. When mTOR interacts with specific adaptor proteins, it forms two complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The mTOR signaling system regulates gene transcription and protein manufacturing to control proliferation of cell, differentiation of immune cell, and tumor metabolism. Due to its vital role in case of microbial infections, inflammations and cancer development and progression, mTOR has been considered as a key therapeutic target for the development of targeted medication. As autophagy dysfunction is linked to changes in both innate and adaptive immune responses, bacterial clearance defects, and goblet and Paneth cell malfunction, all of these changes are linked to inflammatory bowel diseases (IBD) and colorectal cancer (CRC) pathogenesis. Preclinical and clinical data have shown that the inhibition and induction of autophagy have significant potential to be translated into the clinical applications. In IBD and several CRC models, mTORC1 inhibitors have been found effective. In the recent years, a number of novel mTOR inhibitors have been investigated in clinical trials, and a number of drugs have shown considerably enhanced efficacy when combined with mTOR inhibitors. The future developments in the mTOR targeting medications can benefit patients in individualized therapy. Advanced and innovative medicines that are more effective and have lower drug resistance are still in high demand. New findings could be relevant in medicine development, pharmacological modification, or future mTOR inhibitor research. Therefore, the goal of this review is to present a comprehensive account of current developments on the mTOR pathway and its inhibitors, with an emphasis on the management of microbial infections, the treatment of inflammatory bowel disease, and the management of colon cancer.

show abstract

Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease

Cited by 18 publications

References 98 publications

Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments

Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments

Immune–related biomarkers shared by inflammatory bowel disease and liver cancer

mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer

Contact Info

Product

Resources

About